WO2011023013A1 - 可使由蛋白质组成的疣和赘生物溶解消除的药物及其用途 - Google Patents

可使由蛋白质组成的疣和赘生物溶解消除的药物及其用途 Download PDF

Info

Publication number
WO2011023013A1
WO2011023013A1 PCT/CN2010/073628 CN2010073628W WO2011023013A1 WO 2011023013 A1 WO2011023013 A1 WO 2011023013A1 CN 2010073628 W CN2010073628 W CN 2010073628W WO 2011023013 A1 WO2011023013 A1 WO 2011023013A1
Authority
WO
WIPO (PCT)
Prior art keywords
parts
pharmaceutical composition
preparation
real
dissolution
Prior art date
Application number
PCT/CN2010/073628
Other languages
English (en)
French (fr)
Inventor
谭国梁
谭晓晴
谭晓雯
Original Assignee
Tam Kuok Leong
Tam Io Cheng
Tam Io Man
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tam Kuok Leong, Tam Io Cheng, Tam Io Man filed Critical Tam Kuok Leong
Priority to JP2012525865A priority Critical patent/JP2013502443A/ja
Priority to EP10811173.3A priority patent/EP2471541B1/en
Priority to US13/392,267 priority patent/US10251925B2/en
Publication of WO2011023013A1 publication Critical patent/WO2011023013A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539Scutellaria (skullcap)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245Amino benzoic acid types, e.g. procaine, novocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/65Amphibians, e.g. toads, frogs, salamanders or newts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484Glycyrrhiza (licorice)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534Mentha (mint)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/70Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/708Rheum (rhubarb)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • A61K36/756Phellodendron, e.g. corktree
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/12Keratolytics, e.g. wart or anti-corn preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Definitions

  • the present invention relates to a medicament for eliminating the dissolution of diseased tissues and/or pathogens and uses thereof; more particularly, the present invention relates to an external treatment of neoplasms, carbs, acne, tumor lice, and phlegm ⁇ drugs and their uses. Background technique
  • the object of the present invention is to provide a kind of real-time dissolution and dissolution of diseased tissues and pathogens by using folk secret recipes and traditional Chinese medicines, utilizing the pharmacological action and clinical experience inheritance and development of alkaline chemical properties of quicklime in folk secret recipes and traditional medicines. Drugs and their uses.
  • the present invention provides a pharmaceutical composition which can eliminate the dissolution of diseased tissues and/or pathogens, the pharmaceutical composition comprising 1.0-60.0 parts of hydrogen, based on 100.0 parts by total weight. Sodium oxide and / or potassium hydroxide, the balance is water.
  • composition of the present invention may further comprise a compound having a local anesthetic action, for example, 0.25-1.0 part of tetracaine, quercetin, glutinous rice and/or menthol.
  • the pharmaceutical composition of the present invention may be a compound preparation, for example, the pharmaceutical composition of the present invention comprises 1.0-60.0 parts of sodium hydroxide and/or potassium hydroxide, 0-1.0 parts of menthol, 0-0.5 parts of licorice , 0-0.5 parts of baicalein, 0-0.5 parts of berberine, 0-0.5 parts of emodin and/or 0-0.5 parts of excipient carbomer (941); more preferably, the pharmaceutical composition of the invention Including 1.0-60.0 parts of sodium hydroxide and/or potassium hydroxide, 0.01-1.0 parts of menthol, 0.01-0.5 parts of isoliquiritin, 0.01-0.5 parts of baicalein, 0.01-0.5 parts of berberine, 0.01-0.5 parts of rhubarb And/or 0.01-0.5 parts of the excipient carbomer (941).
  • the pharmaceutical composition of the present invention comprises 1.0-60.0 parts of sodium hydroxide and/or potassium hydroxide, 0-1.0 parts of menthol, 0-0.5 parts of
  • a hot water extract of the following traditional Chinese medicine or Chinese medicinal material which has been pulverized may be added to the above pharmaceutical composition to form a compound preparation:
  • the present invention also provides the use of the above pharmaceutical composition for the preparation of a medicament for eliminating the dissolution of diseased tissues and/or pathogens in real time.
  • the present invention provides the preparation of a polyps suitable for real-time dissolution and elimination of condyloma acuminata (CA), infectious soft palate, skin cancer, various tissues and organs, precancerous lesions, nodular pruritus, and ink using the above pharmaceutical composition.
  • CA condyloma acuminata
  • infectious soft palate skin cancer
  • various tissues and organs precancerous lesions
  • nodular pruritus nodular pruritus
  • ink a pharmaceutical composition
  • drugs such as cockroaches, corns, vulgaris, and skin lice.
  • the present invention provides the preparation of the above pharmaceutical composition for real-time dissolution and elimination of herpes, herpes zoster, various stages of rosacea, inflammatory acne, various stages of chronic cervicitis, suppurative sweat gland, abscess, sputum
  • the present invention provides the use of the above pharmaceutical composition for the preparation of a medicament suitable for real-time dissolution to eliminate symptoms such as flat warts, skin tuberculosis, tuberculosis leprosy, age spots, edulis and the like. Further, the present invention provides the use of the above pharmaceutical composition for the preparation of a medicament suitable for real-time dissolution of a drug for eliminating gray nails, crustaceans, dead skin and the like.
  • the present invention provides the use of the above pharmaceutical composition for the preparation of a medicament suitable for real-time dissolution to eliminate symptoms such as neurodermatitis, pityriasis rosea, body spasm, athlete's foot and the like.
  • the invention has the beneficial effects that the invention is based on the folk secret recipe and the traditional Chinese medicine, and combines the modern medical science and technology to dissolve and destroy the diseased tissue and the pathogen in real time, has the advantages of quick effect, remarkable effect and small side effect, and has good application prospect.
  • the invention is further described in the following with reference to the specific embodiments, but the invention is not limited to the embodiments, and any modifications or substitutions of the basic spirit of the invention are still within the scope of the invention as claimed. detailed description
  • a drug that can eliminate the dissolution of diseased tissues and pathogens, measured by weight, and the total amount is set to
  • Sodium hydroxide and potassium hydroxide are capable of solubilizing proteins, and the appropriate concentration thereof can be dissolved in real time to eliminate various diseased tissues and pathogens composed of proteins, which is the basis of the present invention.
  • the pharmaceutical preparation of the present invention may also be added with a compound having a local anesthetic effect, and may be formulated into a compound preparation such as 1.0 part of tetracaine; or 0.5 part of glutinous rice; or 0.75 part of glutinous rice; or 1.0 part of menthol. When used to treat a disease, it can be carried out in painless or mild pain.
  • the present invention can also be added to the vehicle carbomer (941) 0-0.5 parts to make it a compound preparation.
  • the pharmaceutical preparation of the invention may also be added with active ingredients such as traditional Chinese medicine, for example: 0-1.0 parts of menthol, 0-0.5 parts of isoglycyrrhizin, 0-0.5 parts of baicalein, 0-0.5 parts of berberine, 0-0.5 of emodin A portion of the excipient carbomer (941) 0-0.5 parts is used as a compound preparation.
  • the invention can also be added to the traditional Chinese medicine or hot water extract which is ground into fine powder, for example: mint 0-1.0 Parts, licorice 0-3.0 parts, Astragalus 0-3.0 parts, Cork 0-3.0 parts, Rhubarb 0-3.0 parts, and excipient carbomer (941) 0-0.5 parts, make it a compound preparation.
  • licorice (glycyrrhizic acid, isoglycyrrhizin) has antibacterial, antiviral, antitumor, anti-inflammatory, and immunomodulatory effects
  • rhubarb emodin
  • emodin has antibacterial, antiviral, anti-inflammatory and anti-tumor effects
  • Cork has antibacterial and anti-cancer effects.
  • the combination of these Chinese medicines or their active ingredients with sodium hydroxide or potassium hydroxide can enhance the efficacy of the medicine.
  • the preparation of this embodiment can be named as "pharmaceutical No. 1 preparation for dissolving diseased tissues and pathogens", and is also known as a solution for dissolving sputum.
  • the formulation is: 20.0 parts of sodium hydroxide, 1.0 part of tetracaine, and the balance is added to 100.0 parts.
  • This product is characterized by excellent immediate dissolution and elimination of diseased tissues and pathogens. It is suitable for condyloma acuminata (CA), infectious soft palate, skin cancer, polyps of various tissues and organs, precancerous lesions, nodular pruritus, Treatment of ink, eye, common warts, and skin warts.
  • CA condyloma acuminata
  • infectious soft palate skin cancer
  • polyps of various tissues and organs polyps of various tissues and organs
  • precancerous lesions Treatment of ink, eye, common warts, and skin warts.
  • the preparation of this embodiment can be named as "pharmaceutical preparation No. 2 which can dissolve the diseased tissue and the pathogen," and is also called herpes sore.
  • the formulation is: licorice 3.0 parts, jaundice 3.0 parts, cork 3.0 parts, rhubarb 1.0 part, menthol 1.0 part, sodium hydroxide 2.5 parts, ⁇ 1.0 1.0 part, plus excipient carbomer (941 ) 0.25 parts, add water to 100.0 parts.
  • the ingredients are licorice, scutellaria, cork, rhubarb, medlar, and menthol, which are ground into 200 mesh powder.
  • This product can be used for condyloma acuminata. After applying the "drug No. 1 preparation which can dissolve the diseased tissue and pathogens", after removing the large and small granules seen by the naked eye, this product can be used to dissolve the diseased tissue and pathogens.
  • Formulation No. 2 widely applied to the affected area and surrounding areas, to treat the “subclinical” ward of CA, dissolve and eliminate subtle lesions and pathogen HPV virus, and reduce the chance of recurrence. After five to twenty minutes, the drug is wiped off with a distilled water cotton ball to end the treatment.
  • the drug No. 1 preparation and the No. 2 preparation which can dissolve the diseased tissue and the pathogen are combined, and such a pharmaceutical preparation dissolves the condyloma acuminata (including the intrauterine HPV virus) in such a rapid and real-time manner, which is not described in the literatures at home and abroad.
  • Drug No. 2 preparation for dissolving diseased tissues and pathogens suitable for sexually transmitted diseases, herpes zoster, rash, various rosacea, inflammatory acne, chronic cervicitis, suppurative sweat gland, abscess, sputum Warts, inflammatory granuloma, ring granuloma, acne, sporotrichosis.
  • the characteristics of this formula are: If the appropriate number and duration of expectoration are mastered, it can be highly selective for diseased tissues without harming normal tissues.
  • the preparation of the present embodiment can be named as "drug No. 3 preparation for dissolving diseased tissues and pathogens", and the composition of the preparation is: parts of glycyrrhizic acid, 1.0 part of baicalein, 1.0 part of berberine, 1.0 part of emodin, 1.0 part of menthol, 4.0 parts of sodium hydroxide (or potassium hydroxide), 0.5 part of glutinous rice cake, 0.25 parts of vehicle carbomer (941), and water added to 100.0 parts.
  • This product is suitable for flat warts, skin tuberculosis, tuberculosis-like leprosy, age spots, and edema.
  • Treatment of flat warts, contagious soft palate, age spots, edulis, should be marked with a toothpick or a small cotton swab, see the rash zoom black, you can wipe the liquid.
  • This product is diluted 1-10 times with distilled water or mineral water for external use, washed and coated in a small area of I-II degree burn or burn, can quickly relieve pain, remove heat, blister, prevent infection.
  • Example 4
  • the preparation of this embodiment can be named as "pharmaceutical preparation No. 4 which can dissolve the diseased tissue and the pathogen to be dissolved", and the formulation of the composition is:
  • This product is suitable for dissolving gray nails and to dissolve hard skin and dead skin.
  • the preparation may also be relatively small in the patient's local lesions and grow in the less sensitive part of the pain; in the case that the patient has underwent general anesthesia or the diseased tissue has been locally anesthetized, the preparation can be used for local application of a wide range of dissolution. , the pain-sensitive lesion tissue, for rapid, deep dissolution.
  • the "pharmaceutical No. 1 preparation” which can eliminate the dissolution of diseased tissues and pathogens.

Description

可使由蛋白质组成的疣和赘生物溶解消除的药物及其用途 技术领域
本发明涉及一种可使病变组织和 /或病原体溶解消除的药物及其用 途; 更具体地讲, 本发明涉及一种外治赘生物、 恶肉、疽疮、瘿瘤疣子、 痛疥瘙癬的药物及其用途。 背景技术
生石灰又称石灰或氧化钙, 在我国现存最早药物学专著《神农本草 经》 中记载: "主疽疡疥瘙, 热气恶性疮, 癞疾死几堕眉, 杀痔虫, 去 黑子息肉。 "汉末《名医别录》: "疗髓骨疽。 "唐代甄权《药性论》: "治 痛疥, 蚀恶肉, 不入汤服, 止金疮血, 和鸡子白, 败船茹甚良。 ,,宋初 《曰华子本草》 : "生几长肉, 止血, 并主白癜、 疬疡、 瘢疵等, 疗冷 气、 痔瘘疽疮, 瘿瘤疣子"。 生石灰历代广泛用于燥湿、 杀虫、 止血、 定痛、 蚀恶肉、 治疥癬、 湿闪、 创伤出血、 汤火烫伤、 痔疮、 脱肛、 赘 疣, 具有较好的疗效。 发明内容
本发明的目的是基于民间秘方和传统中医药, 利用民间秘方和传统 医药中生石灰之碱性化学性质的药理作用和临床经验继承和发展, 而提 供了一种可使病变组织及病原体实时溶解消除的药物及其用途。 一方面, 为了实现上述的本发明目的, 本发明提供了一种可使病变 组织和 /或病原体溶解消除的药物组合物, 以 100.0份总重量量计, 该药 物组合物包括 1.0-60.0份氢氧化钠和 /或氢氧化钾, 余量为水。
进一步地,上述本发明的药物组合物中可以进一步包括有局部麻醉 作用的化合物, 例如 0.25-1.0份的丁卡因、 蟾酥灵、 蟾酥和 /或薄荷醇。
在一实施方式中, 本发明的药物组合物中 0.01-0.5 份的卡波姆 ( 941 ), 作为其赋形剂。
优选地, 本发明的药物组合物可以成为复方制剂, 例如, 本发明的 药物组合物包括 1.0-60.0份氢氧化钠和 /或氢氧化钾、 0-1.0份薄荷醇、 0-0.5份异甘草素、 0-0.5份黄芩素、 0-0.5份小檗碱、 0-0.5份大黄素和 / 或 0-0.5份赋形剂卡波姆(941 ); 更优选地, 本发明的药物组合物包括 1.0-60.0份氢氧化钠和 /或氢氧化钾、 0.01-1.0份薄荷醇、 0.01-0.5份异甘 草素、 0.01-0.5 份黄芩素、 0.01-0.5 份小檗碱、 0.01-0.5 份大黄素和 /或 0.01-0.5份赋形剂卡波姆 ( 941 )。
本发明中,上述药物组合物中可以加入磨成 粉的如下中药或中药 材的热水抽提物, 成为复方制剂:
0-1.0份薄荷、 0-3.0份甘草、 0-3.0份黄芩、 0-3.0份黄柏和 /或 0-3.0 份大黄; 吏优逸为: 0.01-1.0份薄荷、 0.01-3.0份甘草、 0.01-3.0份黄芩、 0.01-3.0份黄柏和 /或 0.01-3.0份大黄。 该复方制剂优选含有 0-0.5份赋 形剂卡波姆 ( 941 ), 更优选为含有 0.01-0.5份赋形剂卡波姆 ( 941 )。 另一方面, 为了实现本发明的目的, 本发明还提供了采用上述药物 组合物制备使病变组织和 /或病原体实时溶解消除的药物方面的用途。
优选地,本发明提供了采用上述药物组合物制备适用于实时溶解消 除尖锐湿疣(CA )、 传染性软疣、 皮肤癌、 各种组织和器官之息肉、 癌 前病变、 结节性痒疹、 墨痣、 鸡眼、 寻常疣、 皮赘等症状的药物方面的 用途。
进一步地,本发明提供了采用上述药物组合物制备适用于实时溶解 消除性病疱疹、 带状庖疹、各期酒渣鼻、 炎性痤疮、各期慢性子宫颈炎、 化脓性汗腺炎、 脓肿、 痈疖、 炎性肉芽肿、 环状肉芽肿、 疥疮、 孢子丝 菌病等症状的药物方面的用途。
进一步地,本发明提供了采用上述药物组合物制备适用于实时溶解 消除扁平疣、 皮肤结核、 结核样型麻风、 老人斑、 毛嚢炎等症状的药物 方面的用途。 进一步地,本发明提供了采用上述药物组合物制备适用于实时溶解 消除灰指 (趾) 甲、 硬皮、 死皮等症状的药物方面的用途。
进一步地,本发明提供了采用上述药物组合物制备适用于实时溶解 消除神经性皮炎、 玫瑰糠疹、 体癬、 足癬等症状的药物方面的用途。 本发明的有益效果是: 本发明基于民间秘方和传统中医药, 结合现 代医药科学技术, 可使病变组织及病原体实时溶解消除, 疗效快、 效果 显著、 副作用小, 具有较好的推广应用前景。 下面结合具体实施方式, 来进一步说明本发明, 但本发明不局限于 这些实施例, 任何在本发明基本精神上的改进或替代, 仍属于本发明权 利要求书中所要求保护的范围。 具体实施方式
可使病变组织及病原体溶解消除的药物, 按重量计量, 总份量设为
100.0, 其中包括氢氧化钠 1.0-60.0份, 余量加水至 100.0份;
或以氢氧化钾取代氢氧化钠, 份量不变;
或以氢氧化钠与氢氧化钾的混合物取代氢氧化钠, 份量不变。
氢氧化钠、 氢氧化钾能够溶解蛋白质, 其适当的浓度可以实时溶解 消除由蛋白质组成的各种病变组织及病原体, 这是本发明的根据。
本发明药物制剂, 也可以加入有局部麻醉作用的化合物, 制成为复 方制剂, 例如丁卡因 1.0份; 或蟾酥灵 0.5份; 或蟾酥 0.75份; 或薄荷 醇 1.0份。 使其用于治疗疾病时, 可以在无痛或轻痛中实施。 本发明也 可以加赋形剂卡波姆 ( 941 ) 0-0.5份, 使其成为复方制剂。
本发明药物制剂, 也可加入中药等有效成分, 例如: 薄荷醇 0-1.0 份、 异甘草素 0-0.5份、 黄芩素 0-0.5份、 小檗碱 0-0.5份、 大黄素 0-0.5 份、 赋形剂卡波姆(941 ) 0-0.5份, 使其成为复方制剂。
本发明也可加入磨成微粉的中药或热水抽提物, 例如: 薄荷 0-1.0 份、 甘草 0-3.0份、 黄芩 0-3.0份、 黄柏 0-3.0份、 大黄 0-3.0份, 以及 赋形剂卡波姆 ( 941 ) 0-0.5份, 使其成为复方制剂。
上述复方制剂中, 甘草(甘草酸、 异甘草素)有抗菌、 抗病毒、 抗 肿瘤、 抗炎、 及免疫调节作用; 大黄(大黄素)有抗菌抗病毒消炎及抗 肿瘤作用; 黄芩(黄芩素 )抗菌抗病毒抗过敏抗癌作用; 黄柏(小檗碱 ) 有抗菌抗癌作用。以上这些中药或其有效成份与氢氧化钠或氢氧化钾组 成复方制剂, 可以增强药物的疗效。 实施例 1
本实施例的制剂可以命名为 "可使病变组织及病原体溶解消除的药 物 1号制剂", 又名溶疣消赘膏。
以重量份计, 其配方组成为: 氢氧化钠 20.0份、 丁卡因 1.0份, 余 量加水至 100.0份。
本品特征为具有超卓的立即溶解消除病变组织及病原体之作用,适 用于尖锐湿疣(CA )、 传染性软疣、 皮肤癌、 各种组织和器官之息肉、 癌前病变、 结节性痒疹、 墨痣、 鸡眼、 寻常疣、 皮赘的治疗。
治疗尖锐湿疣, 鬼臼毒素 Podophyllotoxin, 为世界卫生组织及中国 国家卫生部推荐的首选药物。 美国施泰福药厂产品称 WARTREC疣敌, 中国贵州汉方制药称疣迪, 其主要成分都是鬼臼毒素。 药品说明书: 局 部外用, 涂搽于患处: 早晚各二次, 连用 3天至疣体发白, 停药观察 4 天, 共 7天为一疗程。 疣体未消退者进行第二疗程。 总计不超过三疗程 ( 21天)。
应用本发明"可使病变组织及病原体溶解消除的药物 1号制剂", 在 治疗男性包皮内板(包括尿道)、 肛门、 女阴 (包括宫颈、 阴道)等部 位湿润多汁的尖锐湿疣, 以棉签涂药, 其效果如烈火溶冰, 花生米大之 疣粒, 十数分钟之内, 迅速溶化成半透明的胶汁, 剩余相当于疣体三分 一大之黑色内核(血根团), 此内核实乃 CA组织之真皮内增生、 扩张 的毛细血管球团, 受药物之作用, 变黑并缩细。 抹净半透明胶汁, 再搽 药数次, 黑色的血根团继续被溶化、 萎缩, 或脱除, 整个过程不过三十 分钟左右, 伤口实时缩细, 数日可愈合, 细小疣粒, 以竹制牙签搽药, 较为准确, 二、 三分钟可溶化根除。 实施例
本实施例的制剂可以命名为 "可使病变组织及病原体溶解消除的药 物 2号制剂", 又称疱疹疮毒立消膏。
以重量份计, 其配方组成为: 甘草 3.0份、 黄芩 3.0份、 黄柏 3.0 份、 大黄 1.0份、 薄荷脑 1.0份、 氢氧化钠 2.5份、 蟾酥 1.0份, 加赋形 剂卡波姆 ( 941 ) 0.25份、 加水至 100.0份。
成份中之甘草、 黄芩、 黄柏、 大黄、 蟾酥、 薄荷脑, 乃磨成 200目 之粉末。
本品可用于尖锐湿疣, 在应用"可使病变组织及病原体溶解消除的 药物 1 号制剂", 化除肉眼所见的大小疣粒后, 应用本品"可使病变组 织及病原体溶解消除的药物 2号制剂", 广泛涂搽患区及周围区域, 处 理 CA之「亚临床」 病区, 溶解消除细微的病灶及病原体 HPV病毒, 减少再发机会。 五至二十分钟后, 以蒸馏水棉球抹去药物, 结束治疗。
可使病变组织及病原体溶解消除的药物 1号制剂及 2号制剂联合应 用, 以这样的药物制剂, 如此快速的实时溶解消除尖锐湿疣(包含疣内 HPV病毒), 国内外文献未有同样记载。
每次复诊, 以数码相机照相, 输入计算机检查, 放大 10-50倍, 观 察是否仍存「亚临床」 病变, 以便继续处理。
"可使病变组织及病原体溶解消除的药物 2号制剂", 适用于性病疱 疹、 带状庖疹、 各期酒渣鼻、 炎性痤疮、 各期慢性子宫颈炎、 化脓性汗 腺炎、 脓肿、 痈疖、 炎性肉芽肿、 环状肉芽肿、 疥疮、 孢子丝菌病。 此 方剂的特征在于: 若掌握恰当的搽药次数和持续时间, 可对患病组织有 高度选择作用而不伤及正常组织。
例如, 治疗性病生殖器疱疹、 带状疱疹, 于涂搽本品后数分钟, 疼痛即减, 患处毒液渐被吸出, 十数分钟疼痛消失。 疱疹消失时间: 最快 5分钟, 最慢 48分钟, 平均 18.77 分钟。 结痂愈合时间: 最快 17 小时, 最慢 38小时, 平均 26.11小时。 这样好的疗效, 国内外文献未 见记载。
例如, 治疗各期酒渣鼻、 炎性脓肿痤疮, 把药剂涂布患区, 数分钟 后即见病变组织开始溶解、 脓液毒汁渗出、 病变缩细、 抹去溶解渗液。 如此再搽药 1-2次, 病损实时消除, 渗出停止。 翌日结痂, 10-14天痂 脱, 重现粉红细嫩新皮。 严重的酒渣鼻如鼻赘期, 可分区、 多次用药, 由表及里, 溶化、 清除赘生物。 目前国内外文献尚未有用这种药物方剂 和方法, 治疗酒渣鼻和颜面炎性痤疮; 其它的治疗酒渣鼻和炎性脓肿痤 疮的药物和方法, 也未取得如此快速疗效。 实施例 3
本实施例的制剂可以命名为 "可使病变组织及病原体溶解消除的药 物 3号制剂", 以重量份计, 其配方组成为: 甘草酸 1.0份、 黄芩素 1.0 份、 小檗碱 1.0份、 大黄素 1.0份、 薄荷脑 1.0份、 氢氧化钠(或氢氧化 钾) 4.0份、蟾酥 0.5份,加赋形剂卡波姆(941 ) 0.25份、再加水至 100.0 份。
本品适用于扁平疣、 皮肤结核、 结核样型麻风、 老人斑、 毛嚢炎。 治扁平疣、 传染性软疣、 老人斑、 毛嚢炎, 宜用牙签或小棉花签准 确涂药, 见皮疹变焦黑, 即可抹去药液。 对于用抗生素治疗数月开始见 效的皮肤结核、结核样型麻风,把本品涂布于皮疹上,数分钟毒汁渗出, 抹去药物, 即见皮损萎缩, 一周后视情况再次涂药治疗, 可明显缩短疗 程; 也适用于治疗神经性皮炎、 玫瑰糠疹、 体癬、 足癬。
本品以蒸馏水或矿泉水稀释 1-10倍外用, 洗、 涂布于小面积 I-II 度烧伤或烫伤, 能迅速止痛、 去热毒、 消水疱、 防感染。 实施例 4
本实施例的制剂可以命名为 "可使病变组织及病原体溶解消除的药 物 4号制剂", 以重量份计, 其配方组成为:
氢氧化钠 (或氢氧化钾) 30.0份, 加蒸馏水至 100.0份。
本品外搽, 可用于溶解灰指 (趾) 甲, 也可用溶解硬皮、 死皮。 本制剂也可于患者局部病变组织相对细小、 长在疼痛较不敏感部 位; 在患者已作全身麻醉或其病变组织已在局部麻醉的情况下, 本制剂 可用于局部涂布溶解范围较广深、 疼痛较敏感的病变组织, 作快速、 深 彻的溶解。其用途用法可参考实施例 1"可使病变组织及病原体溶解消除 的药物 1号制剂"的用途用法。

Claims

权 利 要 求
1、 一种可使病变组织及病原体溶解消除的药物组合物, 其中, 以 100份重量份计, 所述的药物组合物包括 1.0-60.0份氢氧化钠和 /或氢氧 化钾。
2、 如权利要求 1所述的药物组合物, 其中, 所述的药物组合物中 进一步包括有局部麻醉作用的、 0.25-1.0份的丁卡因、 蟾酥灵、 蟾酥和 / 或薄荷醇。
3、 如权利要求 2所述的药物组合物, 其中, 所述的药物组合物中 进一步包括 0.01-0.5份是赋形剂卡波姆 ( 941 )。
4、 如权利要求 1所述的药物组合物, 其中, 所述的药物组合物进 一步包括: 0.01-1.0份薄荷 S享、 0.01-0.5份异甘草素、 0.01-0.5份黄茶素、 0.01-0.5 份小檗碱、 0.01-0.5 份大黄素和 /或 0.01-0.5 份赋形剂卡波姆
( 941 )。
5、 如权利要求 1所述的药物组合物, 其中, 所述的药物组合物进 一步加入磨成 粉的如下中药或中药材的热水抽提物:
0.01-1.0份薄荷、 0.01-3.0份甘草、 0.01-3.0份黄茶、 0.01-3.0份黄 柏和 /或 0.01-3.0份大黄。
6、 如权利要求 5所述的药物组合物, 其中, 所述的药物组合物中 进一步包括 0.01-0.5份是赋形剂卡波姆 ( 941 )。
7、 如权利要求 1-6所述的药物组合物在制备使病变组织和 /或病原 体实时溶解消除的药物方面的用途。
8、 如权利要求 7所述的用途, 其中, 所述的用途是所述药物组合 物在制备适用于实时溶解消除尖锐湿疣(CA )、 传染性软疣、 皮肤癌、 各种组织和器官之息肉、 癌前病变、 结节性痒疹、 墨痣、 鸡眼、 寻常疣、 皮赘的药物方面的用途。 9、 如权利要求 7所述的用途, 其中, 所述的用途是所述药物组合 物在制备适用于实时溶解消除扁平疣、 皮肤结核、 结核样型麻风、 老人 斑、 毛嚢炎的药物方面的用途。
10、 如权利要求 7所述的用途, 其中, 所述的用途是所述药物组合 物在制备适用于实时溶解消除灰指甲、 硬皮、 死皮的药物方面的用途。
PCT/CN2010/073628 2009-08-24 2010-06-07 可使由蛋白质组成的疣和赘生物溶解消除的药物及其用途 WO2011023013A1 (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2012525865A JP2013502443A (ja) 2009-08-24 2010-06-07 タンパク質からなる疣と新生物を溶解して除去できる薬物及びその用途
EP10811173.3A EP2471541B1 (en) 2009-08-24 2010-06-07 Medicine for dissolving and eliminating wart and excrescence consisting of protein and its uses
US13/392,267 US10251925B2 (en) 2009-08-24 2010-06-07 Pharmaceutical composition for dissolving and eliminating pathological tissues and pathogens and its usage

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200910042030.8 2009-08-24
CN2009100420308A CN101991599A (zh) 2009-08-24 2009-08-24 可使病变组织及病原体溶解消除的药物

Publications (1)

Publication Number Publication Date
WO2011023013A1 true WO2011023013A1 (zh) 2011-03-03

Family

ID=43627218

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2010/073628 WO2011023013A1 (zh) 2009-08-24 2010-06-07 可使由蛋白质组成的疣和赘生物溶解消除的药物及其用途

Country Status (5)

Country Link
US (1) US10251925B2 (zh)
EP (1) EP2471541B1 (zh)
JP (1) JP2013502443A (zh)
CN (3) CN113082046A (zh)
WO (1) WO2011023013A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102247335B (zh) * 2011-06-02 2013-04-17 江苏省中医药研究院 一种蟾毒灵干粉吸入剂及其制备方法、应用
AU2015402192B2 (en) 2015-07-10 2021-06-10 Infectopharm Arzneimittel Und Consilium Gmbh Use of potassium hydroxide in the treatment of actinic keratosis
GB201512410D0 (en) * 2015-07-16 2015-08-19 Univ Plymouth Method
CN105943552A (zh) * 2016-06-17 2016-09-21 王枝宝 一种氢氧化钾的医药用途
PL3691688T3 (pl) 2017-10-06 2022-04-19 Laboratorio Reig Jofré, S.A. Kompozycje hydrożelowe do leczenia molluscum contagiosum
CN107898856A (zh) * 2017-11-27 2018-04-13 内蒙古东达獭兔循环产业研究院 一种治疗兔子真菌病的药物组合物、兔子饲料及制备方法
CN108295088A (zh) * 2018-04-18 2018-07-20 董新声 一种用于寻常疣的外用药及使用方法
CN110025739A (zh) * 2019-06-05 2019-07-19 袁宗生 一种治疗瘊子、扁平疣的组合物及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101433617A (zh) * 2007-11-13 2009-05-20 谭国梁 一种溶疣消赘消毒膏

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4055660A (en) * 1974-06-26 1977-10-25 Meierhenry Dwight W Treatment for warts
JPS62207212A (ja) * 1986-03-08 1987-09-11 Nippon Haipotsukusu:Kk 抗アレルギ−剤
US5433950A (en) * 1990-05-07 1995-07-18 Schering-Plough Healthcare Products, Inc. Flexible collodion compositions
CN1093576A (zh) * 1993-12-24 1994-10-19 肖林章 消痣膏及其配制方法
CN1065430C (zh) * 1997-09-20 2001-05-09 侯润安 一种治疣糊剂
CN1103230C (zh) * 1999-03-25 2003-03-19 项观相 一种治疗黑痣、雀斑、老年斑、扁平疣的外用膏剂及其制备方法
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
AU2002363954B2 (en) * 2001-11-29 2008-04-03 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
CN100340283C (zh) * 2002-04-15 2007-10-03 山东哲夫 用于皮炎治疗的化妆水
CN1209152C (zh) * 2003-03-31 2005-07-06 刘振杰 一种除疣痣组合物及其制备方法
US20080031929A1 (en) * 2005-07-28 2008-02-07 Baggett Richard W Liquid bandage
KR100812596B1 (ko) * 2006-12-15 2008-03-13 바이오스펙트럼 주식회사 천연 유래 화합물을 포함하는 피부보호 조성물
US8535738B2 (en) * 2007-12-20 2013-09-17 Elc Management, Llc Methods and compositions for treating skin
WO2009097512A1 (en) * 2008-02-01 2009-08-06 Innovative Drug Discovery Inc. Herbal pharmaceutical compositions to treat inflammation and inflammation associated conditions and diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101433617A (zh) * 2007-11-13 2009-05-20 谭国梁 一种溶疣消赘消毒膏

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Records of Famous Physicians", HAN DYNASTY
"Rihuazi Herbal", SONG DYNASTY
See also references of EP2471541A4
ZHEN QUAN: "Theory of Medicine Performance", TANG DYNASTY

Also Published As

Publication number Publication date
EP2471541A4 (en) 2013-03-20
US20120189718A1 (en) 2012-07-26
JP2013502443A (ja) 2013-01-24
EP2471541A1 (en) 2012-07-04
CN113082046A (zh) 2021-07-09
CN101991599A (zh) 2011-03-30
US10251925B2 (en) 2019-04-09
CN104940225A (zh) 2015-09-30
EP2471541B1 (en) 2023-05-10

Similar Documents

Publication Publication Date Title
WO2011023013A1 (zh) 可使由蛋白质组成的疣和赘生物溶解消除的药物及其用途
CN103505656B (zh) 一种治疗口腔炎的中药制剂
CN107456509B (zh) 一种用于女性阴道预防、保健以及治疗妇科生殖道炎症的外用生物制剂以及制备方法
CN101874809A (zh) 一种使用甘油dmso混合溶剂的局部抗炎外用药物组合物
CN102755573A (zh) 一种治疗灰指甲的外用中药
CN103610817A (zh) 一种肛门洗液
CN105213353B (zh) 含有薁磺酸钠的复方口腔膜剂及制备方法
CN1189197C (zh) 一种具有消炎止血止痛活血生肌的中药
CN103520262B (zh) 一种脂溶性妇科凝胶
CN103110707B (zh) 一种消肿拔毒的中药巴布贴
CN104474528A (zh) 用于引流排毒的药物
CN1183950C (zh) 治疗烧伤的中药制剂
CN108938703A (zh) 快速抗菌的妇科凝胶
CN107596132A (zh) 一种用于治疗烧伤、烫伤的药物组合物及其制备方法和应用
CN102028771A (zh) 一种紫红疡油膏
CN107638497B (zh) 一种治疗毒蛇咬伤的中药组合物及其制备方法和用途
CN103611007A (zh) 一种药膏及其制备方法
CN1274331C (zh) 一种治疗尖锐湿疣的合剂
CN108354998B (zh) 一种治疗盆腔炎的提取物及其制备方法
CN105456708A (zh) 一种用于治疗口唇炎的药物及其制备方法
CN105617273A (zh) 一种用于促进伤口愈合的药物制剂及其用途
CN105267683A (zh) 一种治疗阴虚毒恋型肛门直肠周围脓肿的中药制剂
CN104887702A (zh) 一种治疗皮肤外伤及溃烂的中药组合物及其制备方法
CN113491755A (zh) 治疗宫颈hpv感染的联合用药方剂
CN101095752B (zh) 治疗烧伤、烫伤的中药药物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10811173

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012525865

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2010811173

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13392267

Country of ref document: US